Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients

Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

(2013) Maurizio Cutolo et al.   AUTOIMMUNITY REVIEWS

CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients

(2013) Jennifer Pieper et al.   BMC IMMUNOLOGY

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

(2013) C. Warnke et al.   NEUROLOGY

Pathogenic features of CD4+CD28– T cells in immune disorders

(2012) Bieke Broux et al.   TRENDS IN MOLECULAR MEDICINE

Targeting CD4+CD28− T cells by blocking CD28 co-stimulation

(2012) Paolo Airò et al.   TRENDS IN MOLECULAR MEDICINE

Baseline Numbers of Circulating CD28-negative T Cells May Predict Clinical Response to Abatacept in Patients with Rheumatoid Arthritis

(2011) MIRKO SCARSI et al.   JOURNAL OF RHEUMATOLOGY

Recent thymic emigrants are preferentially incorporated only into the depleted T-cell pool

(2011) E. G. Houston et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clonal expansions in selected TCR BV families of rheumatoid arthritis patients are reduced by treatment with the TNFα inhibitors etanercept and infliximab

(2010) Matthias Pierer et al.   RHEUMATOLOGY INTERNATIONAL

Telomerase insufficiency in rheumatoid arthritis

(2009) H. Fujii et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES